GenesyzeEnd to End Evidence Generation SolutionsMarket Penetration

Genesyze

Meeting the evidence requirements of healthcare budget holders

Overcoming common barriers to health technology product adoption

Demonstrating value realisation

Price pressure



Your Problem:

Meeting the evidence requirements of healthcare budget holders

Our Solution:

Fast track delivery of evidence to meet requirements for product adoption.

RWE Genesys Services

Medical affairs consultancy
HEOR consultancy
Health economics and outcomes research design, initiation and management
Comparisons between a new therapeutic scenario and the pervading standard of care
Data collection, assimilation and integration
Data de-identification
Data hosting and management
Data analytics
Cost effectiveness studies
Cost impact studies
Systematic reviews
Statistical programming
Evidence dissemination plans with integrated medical writing services

The RWE Genesys Toolkit

Journal publications
White papers
Helpdesk support to study sites
Deidentification apps
Data collection apps: POC and PRO
Data collection hardware
Customised reporting tools
Analytics tools: relational; graph; statistical
Predictive models
SAS apps
CDISC mapping

curve

GenesyzeEnd to End Evidence Generation SolutionsMarket Penetration

Market Penetration

Partnering industry to optimise product adoption by the healthcare community and ensure the right patient receives the right treatment at the right time.

Product Lifecyle Steps

Click on a solution below to discover more...

Genesyze

Product
Discovery



 

Genesyze

Market
Entry



 

Genesyze

Market
Penetration



 

Genesyze

Patient
Access

BACK TO PRODUCT LIFECYCLE OVERVIEW

REACH OUT TODAY

Arrange a call back...

curve

Latest News

Feb 1, 19

Colette Hamilton, CEO and Principal Economist, will be providing economic support to the Integrated European Network on Chronic Graft Versus Host Disease (cGvHD), a major cause of non-relapse morbidity and mortality following allogeneic haematopoietic stem cell transplantation.

Colette Hamilton, CEO and Principal Economist, will be providing economic support to the Integrated European Network on Chronic Graft Versus Host Disease (cGvHD), a major cause of non-relapse morbidity and mortality following allogeneic haematopoietic stem cell transplantation.

Read more about the Integrated EU Network

Jan 3, 19

Talk of Manchester Business Awards 2019. CEO, Colette Hamilton presents Best Digital Agency and Best Business Awards at the Talk of Manchester Business Awards on Thursday 6th December to a huge turn out. #theTOMs supporting Kidscan charity

Talk of Manchester Business Awards 2019. CEO, Colette Hamilton presents Best Digital Agency and Best Business Awards at the Talk of Manchester Business Awards on Thursday 6th December to a huge turn out. #theTOMs supporting Kidscan charity

Read

Mar 19, 18

Colette Hamilton, CEO, speaker at sponsored event, Pharma Pricing & Market Access EU 2018. Talk title; Redefining HEOR practice to meet the needs of a 21st century healthcare system:the economist’s perspective.

Colette Hamilton, CEO, speaker at sponsored event, Pharma Pricing & Market Access EU 2018. Talk title; Redefining HEOR practice to meet the needs of a 21st century healthcare system:the economist’s perspective.

Read

Mar 18, 18

CEO Colette Hamilton attends the UK’s first LinkedInLocal networking event in the North, at the UKFast headquarters. Exciting collaborations in Manchester, the heart of the UK’s Northern Tech Powerhouse

CEO Colette Hamilton attends the UK’s first LinkedInLocal networking event in the North, at the UKFast headquarters. Exciting collaborations in Manchester, the heart of the UK’s Northern Tech Powerhouse

Read

This website uses cookies to give you the best experience. If you continue to use this site, we’ll assume that you’re happy to receive all cookies. View our Cookie Policy here.